Norwegian Weifa to sell AFT’s pain and fever drugs in the Nordic region

Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).

The products will cover a patented fixed ratio of ibuprofen and paracetamol, and covers tablet, sachet and oral liquid formulations. The Norwegian company will sell them under its own brand name.

AFT Managing Director, Dr Hartley Atkinson, said that Weifa he’s pleased to see Weifa dealing with AFT’s product in the $165 million worth market. “We look forward to taking substantial market share through our alliance with Weifa. We aim to launch this coming FY2018 time period,” said Atkinson.

Kathrine Gamborg Andreassen, Chief Executive Officer at Weifa, said:“We are delighted to sign this new alliance agreement with AFT. AFT’s product line represents a unique novelty for the Nordic market and will contribute greatly to Weifa’s analgesic portfolio.  The success of our Nordic strategy depends on the commercialization of highly innovative products which meet the needs of consumers and pharmacies.”